ArticleClinical case reports2026
Coexistence of Friedreich's Ataxia and Esophageal Cancer: A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Friedreich's ataxia (FA) is a rare autosomal recessive neurodegenerative disorder. Although FA is frequently associated with cardiomyopathy and diabetes mellitus, its coexistence with solid malignancies is exceptionally rare. To date, only a limited number of gastrointestinal cancers have been reported in patients with FA. This case report presents the first documented occurrence of esophageal squamous cell carcinoma (ESCC) in a genetically confirmed FA patient, highlighting the diagnostic challenges and therapeutic considerations encountered in this unique clinical setting. A 48-year-old Iranian man with a 29-year history of Friedreich's ataxia presented with an 8-month history of progressive dysphagia, recurrent hematemesis, and recent onset of complete aphagia. On examination, he was cachectic and exhibited severe alopecia, kyphoscoliosis, dysarthria, and a non-ambulatory status. Laboratory evaluation demonstrated profound anemia and elevated alkaline phosphatase levels. Upper gastrointestinal endoscopy revealed a circumferential, obstructing mass in the mid-esophagus, and histopathological analysis confirmed moderately differentiated ESCC. Given the patient's advanced frailty, underlying cardiomyopathy, and severe malnutrition, curative chemoradiotherapy was deemed contraindicated. Palliative management included blood transfusion, nasogastric decompression, and placement of an esophageal stent. Despite these supportive interventions, the patient experienced hemodynamic instability and progressive neurological deterioration, ultimately succumbing to disease progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.